Purple Biotech's IM1240 Shows Promising Preclinical Data in Cancer Resistance Models — Purple Biotech Ltd.

Event summary

Purple Biotech presented preclinical data at EACR 2026 showing IM1240's anti-tumor activity in PD-1- and chemotherapy-resistant patient-derived samples across head and neck, bladder, and lung cancers.
IM1240 demonstrated an 8-fold longer half-life and 16-fold greater exposure compared to the non-capped variant, with a markedly improved cytokine-release safety profile.
The CAPTN-3 masking strategy induced mature tertiary lymphoid structures (TLS) and immune cell remodeling in NSCLC explants, highlighting the critical role of the NKG2A arm.
Non-GLP toxicology study in NHPs validated the CAPTN-3 masking strategy, supporting the planned advancement of IM1240 toward a first-in-human clinical study in 2027.

The big picture

Purple Biotech's IM1240 represents a next-generation immunotherapy platform designed to overcome resistance in hard-to-treat cancers. The CAPTN-3 masking strategy addresses key safety challenges of T-cell engagers, potentially expanding the therapeutic window and improving patient outcomes. The data presented at EACR 2026 underscore the growing focus on combination immunotherapies and the need for innovative solutions in oncology.

What we're watching

Clinical Translation: Whether IM1240's preclinical efficacy and safety profile will translate into successful first-in-human trials starting in 2027.
Competitive Differentiation: How the NKG2A arm's contribution to anti-tumor activity will position IM1240 against existing and emerging therapies for PD-1-resistant cancers.
Regulatory Pathway: The pace at which Purple Biotech can advance IM1240 through clinical stages, given the favorable preclinical data and broad therapeutic window.